Gastro-esophageal reflux. Gastro-esophageal reflux disease
Conditions
Interventions
Intervention 1: Intervention group: In this group, pantoprazole 40 mg before breakfast and acetylene 60 mg before bedtime, is used. Intervention 2: Control group: In this group, pantoprazole 40 mg bef
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Completion of informed consent form Diagnosis of reflux disease is confirmed by clinical and paraclinical findings. The patient's condition is not life-threatening. Do not participate in another clinical trial at the same time. Do not interact with medication before intervention. Like beta blocker inhibitors and herbal medicines or drugs that are harmful for treatment of reflux, such as theophylline, and others. Age over 18 years No smoking in the past Not pregnancy Failure to enter the plan for patients with psychiatric and veterinary injuries due to pulmonary symptoms
Exclusion criteria
Exclusion criteria: The occurrence of severe drug-related symptoms and severe hypersensitivity to drugs that can not be controlled. Signs and symptoms of the patient have worsened during the study. Those patients who have not consumed their medication for more than a week. History of chemical gas and severe pulmonary disease. Pregnant or intending to have a pregnancy Presence and observation of drug interactions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptoms of Gastro-esophageal reflux Disease. Timepoint: Before starting treatment, as well as at 3 and 6 weeks after starting treatment. Method of measurement: Interview with patients using reflux symptom index questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hossein Khammat
Bagheiat-allah University of Medical Sciences
Outcome results
None listed